Anti-CTLA-4 (ipilimumab) is also be used in lung cancer because of CTLA-4 as a checkpoint on lymphocytes (Ackermann et al., 2019; Dawe et al., 2020; Peng et al., 2022). The gene discussed is CTLA4; the disease is lung carcinoma.